MASCC Risk Index for Febrile Neutropenia

The MASCC Risk Index for Febrile Neutropenia identifies patients at low risk for serious complications to guide safe outpatient management 1.

Burden of illness (symptom severity)
Severe0Moderate+3None or mild+5
Hypotension (sBP < 90 mmHg)
Yes0No+5
Active COPD
Yes0No+4
Type of cancer
Hematologic, prior fungal infection0Hematologic, no prior fungal infection+4Solid tumor+4
Dehydration requiring IV fluids
Yes0No+3
Status at onset of fever
Inpatient0Outpatient+3
Age (years)
≥ 600< 60+2

Indicaciones de Uso

Used for adults with cancer and new febrile neutropenia to identify low‑risk patients (score ≥21) who may be safely considered for early discharge and outpatient oral antibiotics when clinically stable, per ASCO/IDSA guidance 1 [Level I evidence] and validated in the original multinational cohort showing PPV 91% and sensitivity 71% for low‑risk classification 2 [Level I evidence].

Información y Precauciones

Identifies low‑risk episodes suitable for outpatient care but can miss complications. In the original multinational validation, score ≥21 yielded PPV 91%, sensitivity 71%, specificity 68% 1 [Level I evidence]. Performance drops in some real‑world or high‑comorbidity cohorts, with sensitivity as low as 45% and PPV 11% 2 [Level II evidence]. Underestimates risk in “apparently stable” FN compared with CISNE 3 [Level II evidence]. Use only with clinical judgment and social/medical exclusion criteria.